PSA Test: Results, Normal Ranges & Prostate Cancer Screening

The PSA test measures prostate-specific antigen levels in the blood and is a widely used screening tool for prostate cancer and benign prostate conditions. While elevated PSA can indicate cancer, it may also result from prostatitis, benign prostatic hyperplasia (BPH), or recent activities like cycling or ejaculation. Understanding PSA results requires considering age, family history, and other clinical factors to determine appropriate follow-up.

How to interpret your results

There is no single PSA threshold that cleanly separates “normal” from “abnormal.” The same number can mean different things depending on age, prior PSA history, the medications you take, and what you did in the days before the draw. In general, the higher the PSA, the more likely cancer is present — but you can have a high PSA without cancer, or a low PSA with cancer.

When you look at your result, three pieces of context matter alongside the number. First, the trajectory — is this higher than your last PSA, and how quickly did it climb? Second, what you did in the 48 hours before the draw — ejaculation, vigorous exercise, or a recent prostate procedure can raise PSA temporarily. Third, the medications you take, since some artificially lower the result.

Why trajectory matters more than a single number

PSA can rise temporarily for reasons unrelated to cancer: a recent prostate infection, a recent biopsy, cycling, or ejaculation a day or two before the test. A borderline reading can become reassuring or concerning once those are added in. This is why providers typically confirm an elevated PSA with a second draw rather than acting on a single result.

If your PSA continues to rise — especially if it rises quickly — your provider is likelier to recommend further evaluation. PSA levels go up and down; changes over time matter more than any single value.

Total PSA and free PSA

Two related measurements may appear on your report: total PSA and free PSA, which together make up the total. Most screening discussions and reference cutoffs refer to total PSA. If free PSA was also ordered, it appears as a separate number on the same panel. Ask the clinician how they intend to use that value — interpretation depends on the broader workup, not on free PSA in isolation.

How to prepare for a PSA test

Several everyday activities can raise PSA and make a result look worse than it is. Avoid them for at least 48 hours before your draw — the NHS timing, consistent with the National Cancer Institute’s “wait 2 days” guidance. MedlinePlus uses a 24-hour window for sexual abstinence; the longer window is safer.

In the 48 hours before your test, avoid:

• Ejaculation (sex or masturbation) — releasing semen can transiently raise PSA
• Anal sex
• Vigorous exercise, especially cycling — anything leaving you out of breath
• Recent prostate procedures — a biopsy can keep PSA elevated for a month or two; tell your provider

You do not need to fast for a PSA test. You can eat and drink as usual. The blood draw itself takes less than five minutes.

Tell your provider about every medication you take. 5-alpha reductase inhibitors — finasteride and dutasteride, used to treat benign prostatic hyperplasia — artificially lower PSA, and a different cutoff may apply if you take them. Do not stop any medication on your own. If a digital rectal exam (DRE) is part of the visit, your provider will usually conduct it alongside the PSA test.

The PSA screening debate: benefits and harms

Whether men without symptoms should routinely be screened is genuinely unsettled. Major medical bodies have arrived at different answers; most organizations now recommend the decision be made together with a clinician after weighing the benefits and harms.

The U.S. Preventive Services Task Force (USPSTF) issued its current recommendation in 2018, applying both to the general population and to higher-risk groups:

• Ages 55 to 69: the decision to screen should be individual, made after a clinician discusses the potential benefits and harms in the context of the patient’s own values
• Ages 70 and older: PSA-based screening is not recommended

The contrast with other systems is informative. The NHS does not offer routine PSA screening; testing is reserved for men with symptoms, or available on request to men aged 50 or over after they understand the trade-offs. Some specialty groups recommend earlier screening for higher-risk men, starting at age 40 or 45. The higher-risk groups include Black men, men with a father or brother who had prostate cancer, and men with inherited BRCA2 (and to a lesser extent BRCA1) variants.

Why reasonable people disagree

The disagreement comes down to weighing real benefits against real harms. PSA screening leads to a small reduction in prostate-cancer mortality over roughly a decade. It also produces frequent false positives and identifies slow-growing cancers that would never have caused symptoms — a problem called overdiagnosis.

USPSTF modelling: per 1,000 men aged 55–69 screened over 13 years:

About 6–7% of men have a false-positive PSA on any given round, and only about 25% of biopsies prompted by an elevated PSA actually find cancer. Whether the small mortality benefit outweighs the burden of false positives, biopsy complications, and possible overtreatment is a judgement call each guideline body weighs differently.

Refinements after a borderline PSA

A single total-PSA number is a blunt instrument. When the result falls into a borderline zone, providers often turn to refinements before deciding on a biopsy. The sharper question those refinements try to answer is whether the elevation is more likely cancer or benign.

The most established next step is simply repeating the PSA. If the second value stays elevated and continues to rise — especially if it rises quickly — that pattern is more concerning than a number that holds steady. Continued observation with repeat PSAs and DREs is NCI’s standard pathway after one abnormal result.

Newer biomarker panels

Beyond repeating the PSA, several blood and urine panels are used to triage borderline results:

• Prostate Health Index (PHI) — a blood test combining PSA measurements to estimate biopsy need
• IsoPSA — assesses risk of high-grade prostate cancer
• 4Kscore — assesses risk of aggressive prostate cancer after an abnormal screening result
• PCA3 and ExoDx (urine-based) — biomarkers used after an abnormal PSA or DRE to help decide on biopsy

None of these tests has yet been proven to reduce death from prostate cancer, and availability varies by country and insurer. Their role is to help avoid unnecessary biopsies, not to replace the PSA test.

Imaging before biopsy

Imaging tests, including magnetic resonance imaging (MRI) and high-resolution micro-ultrasound, may be recommended before a biopsy when PSA continues to rise. If MRI shows a suspicious area, an MRI-guided biopsy may be performed. Integrating MRI into PSA-based screening is itself an active research area.

What happens if your PSA is elevated

A single elevated PSA is rarely a cause for immediate alarm or biopsy. The standard pathway when a screening result comes back abnormal is stepwise:

1. Repeat the PSA in 6 to 8 weeks to confirm the original finding
2. Continue monitoring with repeat PSA tests and digital rectal exams to track changes over time
3. Add other tests if PSA keeps rising or the DRE finds something — MRI, micro-ultrasound, or additional blood and urine biomarkers
4. Biopsy if a suspicious area is found or PSA continues to climb; an MRI-guided biopsy may be used when MRI shows a target

PSA can rise temporarily for reasons unrelated to cancer. Common benign drivers include prostatitis, benign prostatic hyperplasia (BPH), and urinary tract infections — alongside ejaculation, cycling, or a recent biopsy. Because inflammation alone can raise the result, your provider may wait for an active infection to resolve before re-drawing. A separate inflammation marker like CRP is sometimes useful for tracking inflammation more broadly, though it isn’t a routine pre-PSA test.

When the number is concerning

If your PSA is rising sharply between tests, the next step is typically prompt urology referral and more testing. That shifts the timeline from a watchful repeat months out to a sooner workup. PSA is not itself a diagnosis — it is one of several organ-specific tumor markers used to monitor disease, alongside others like CEA. Receiving an elevated number on a portal can be frightening; the right next step is a same-week call with your clinician, not online searching. Bring the result, your prior PSA history, and a list of medications and activities that could have influenced it.

Frequently asked questions

What does PSA stand for?

PSA stands for prostate-specific antigen — a protein made by the prostate gland and found in semen. The blood test measures how much PSA is circulating, reported in nanograms per millilitre (ng/mL). Both normal and cancerous prostate tissue produce PSA, which is why a single value alone cannot diagnose cancer.

What should I avoid before a PSA test?

For 48 hours before the test, avoid ejaculation, anal sex, and any exercise vigorous enough to leave you out of breath — cycling is the most-cited example. Tell your provider about all medications, particularly finasteride or dutasteride, which lower PSA. You do not need to fast.

How long does it take to get PSA test results?

Most PSA results come back within 1 to 2 weeks. If you haven’t heard after a few weeks, contact the clinic that drew the blood. Some labs return results faster through an online portal or app, and you may be able to view yours there before your provider reaches out.

Where can I get a PSA test?

A PSA test is usually done at your GP surgery, primary care office, or local hospital, by a nurse or other healthcare professional. In the U.S., Medicare covers an annual PSA test for eligible individuals over 50, and many private insurers cover screening as well.

Is the PSA test as good as a digital rectal exam?

They are complementary, not interchangeable. Providers typically perform a digital rectal exam (DRE) alongside the PSA test rather than choosing one. MedlinePlus also lists the DRE among follow-up steps when PSA results are abnormal. NHS guidance describes the DRE as a routine companion procedure when prostate symptoms are being assessed.

How long does the PSA blood test itself take?

The blood draw takes less than five minutes. A healthcare professional collects a small sample from a vein in your arm using a thin needle. You may feel a brief sting as the needle goes in or out, with possible mild bruising afterward; risks are minimal.

Is PSA testing routine on the NHS?

No. Routine PSA testing is not offered on the NHS. Men aged 50 or over with a prostate can request a PSA test from their GP without symptoms, after discussing the benefits and risks. The NHS frames the test as a shared decision rather than a default screening offer, in part because of false-positive risks.

When to talk to your doctor

Book an appointment promptly if you have any of the following — symptoms that authoritative guidance flags as warranting evaluation, regardless of where you stand on the screening debate:

• Blood in your urine or semen
• Painful, slow, or unusually frequent urination, including getting up often at night to pee
• A sudden, urgent need to pee or new urinary incontinence
• Pelvic or lower-back pain with no obvious explanation
• New difficulty getting or maintaining an erection
• A PSA that has risen sharply since your last test, or that your provider judges unusual for your age and history
• A first-degree family history of prostate cancer, or known BRCA1 or BRCA2 variants — warrants a conversation about earlier screening
• Black men aged 40 or older considering screening — higher baseline risk changes the benefit-harm calculation

If you fall in the 55–69 age band and have not yet had the screening discussion, the USPSTF recommends making the decision with your clinician, after weighing the benefits and harms against your own values. The conversation is the point — no single right answer applies to everyone in this age range.

References

• MedlinePlus (U.S. National Library of Medicine, NIH)
• Cleveland Clinic
• NHS (UK National Health Service)
• Peer-reviewed reference

Last reviewed: 2026-05-12